特集 神経疾患治療の進歩2024
運動ニューロン疾患の治療の進歩
キーワード:
motor neuron disease,
amyotrophic lateral sclerosis,
spinal and bulbar muscular atrophy,
spinal muscular atrophy,
clinical trial
2025 年 42 巻 5 号 p. 828-831
詳細
2025 年 42 巻 5 号 p. 828-831
Motor neuron diseases (MND) are devastating neurodegenerative disorders that primarily affect motor neurons, including amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), and spinal bulbar muscular atrophy (SBMA). In 2024, based on the results of the JETALS trial, ultrahigh–dose methylcobalamin therapy was approved in Japan for ALS. This review provides a comprehensive overview of the clinical advancements in MND research and summarizes key literature on therapeutic approaches from 2024.
